Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference
Cognition Therapeutics (Nasdaq: CGTX) will present at the JMP Securities Life Sciences Conference on June 16, 2022. CEO Lisa Ricciardi will provide an update on the development of small-molecule therapeutics for age-related degenerative diseases. The presentation will focus on their lead candidate, CT1812, which is being studied in clinical programs targeting Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration. A live and archived webcast will be available online.
- Participation in the JMP Securities Life Sciences Conference may enhance the company's visibility and attract investor interest.
- Focused on developing CT1812 for significant conditions like Alzheimer's disease and dry AMD, potentially addressing unmet medical needs.
- No financial metrics or specific results from ongoing clinical trials were disclosed, which may leave investors uncertain about progress and prospects.
PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lisa Ricciardi, Cognition’s president and CEO will be presenting an update on the company's progress developing small-molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. A live and archived webcast can be accessed here as well as on the company’s Events & Presentations webpage.
| Presentation details: | |
| Location: | Lotte New York Palace Hotel, Holmes II |
| Date: | Thursday, June 16 |
| Time: | 12:30 PM |
About Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and are available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact Information:
Cognition Therapeutics, Inc.
info@cogrx.com
Aline Sherwood (media)
Scienta Communications
asherwood@scientapr.com
Lisa Sher/Daniel Kontoh-Boateng (investors)
Tiberend Strategic Advisors, Inc.
lsher@tiberend.com/ dboateng@tiberend.com
FAQ
When will Cognition Therapeutics present at the JMP Securities Life Sciences Conference?
Who will present for Cognition Therapeutics at the conference?
What is the focus of Cognition Therapeutics' presentation at the conference?
What is the lead candidate being discussed by Cognition Therapeutics?
What diseases is CT1812 targeting?
